Headquartered in An Der Goldgrube 12, Mainz Fiscal year ends December NASDAQ: BNTX biontech.de
BioNTech SE is a next-generation immunotherapy company developing medicines against cancer, infectious diseases and other serious diseases.
**Technology and operating model**
- Platforms span mRNA immunotherapies (FixVac, RiboMab, RiboCytokine) and protein-based therapeutics, including monoclonal and bispecific antibodies and antibody-drug conjugates (ADCs).
- The integrated model combines research, GMP manufacturing (including modular BioNTainer facilities), clinical development, commercial capabilities and AI/ML.
- AI capabilities from InstaDeep, acquired in July 2023, are being folded into the core business.
**Commercial product**
- Its only marketed product is the COVID-19 vaccine Comirnaty, sold with Pfizer, which handles commercialization outside Germany and Türkiye.
- Fosun Pharma holds rights in Greater China.
- Revenue is mainly BioNTech's share of Pfizer's gross profit from Comirnaty, based partly on preliminary Pfizer estimates.
- Additional revenue comes from out-licensing and pandemic-preparedness work for the German government.
- The company acquired Biotheus in January 2025, expanding its operations in China, and CureVac in December 2025 through a public exchange offer.
**Strategic focus: oncology**
- The lead asset is pumitamig (BNT327), a PD-L1xVEGF-A bispecific co-developed with Bristol Myers Squibb in seven global registrational trials.
- ADCs partnered with DualityBio and MediLink include trastuzumab pamirtecan, elfetabart drozuntecan, sacituzumab drozuntecan and beruzatatug pelitecan.
- mRNA cancer immunotherapies include the iNeST and FixVac platforms.
- Gotistobart is partnered with OncoC4.
**Infectious disease**
- Programs cover HSV, tuberculosis, mpox and HIV, partly funded by the Gates Foundation and CEPI.
**Restructuring**
- The company is prioritizing its pipeline, consolidating manufacturing sites and divesting non-core businesses such as JPT Peptide Technologies.
**Listing and ownership**
- BioNTech's ADSs trade on the Nasdaq Global Select Market.
- As an operator of German critical infrastructure, it is subject to foreign-investment screening for significant stakes acquired by non-EU/non-EFTA investors. Updated
The first profitable quarter in two years rests on licensing: a $613 million recognition on the Bristol Myers Squibb pumitamig deal carried the beat. Track the oncology launch timeline rather than the headline numbers.
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.52, up 5% in afternoon trading, as the…
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands…
Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.…
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA | MRNA…
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on…
Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10%…
Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…
Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company’s…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy,…
BioNTech SE is a next-generation immunotherapy company developing medicines against cancer, infectious diseases and other serious diseases. **Technology and operating model** - Platforms span mRNA immunotherapies (FixVac, RiboMab, RiboCytokine) and protein-based therapeutics, including monoclonal and bispecific…
24/7 Wall St.'s 12-month price target for BNTX is $130.31, rated Buy. The Wall Street consensus target is $117.29. BNTX price prediction →
